A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

NCT03294083 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: Pexastimogene Devacirepvec (Pexa-Vec)
BIOLOGICAL: Cemiplimab

Sponsor

SillaJen, Inc.

Collaborators

[object Object]